Atyr Pharma Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2026 to a ratio of 0.27, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the second quarter 2026. Average receivable collection period, for the Atyr Pharma Inc in Jun 30 2026 quarter, has decreased to 1352 days, compared to 1404 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector Atyr Pharma Inc achieved the highest receivable turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. .

What is Receivable Turnover Ratio?
What is Atyr Pharma Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ATYR Receivables Turnover Ratio	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Receivable Change	-14.46 %	-51.72 %	-49.71 %	-43.09 %	-69.41 %
Y / Y Revenue Change	-	-	-	-	-
Receivable Turnover Ratio (TTM)	0.27	0.26	0.22	0.18	-
ATYR's Total Ranking	#	#	#	#	#
Accounts Receivable average collection period days	1353	1388	1633	2048	-
Seq. Receivable Change	-10.69 %	-45.36 %	-16.22 %	109.24 %	-49.6 %
Seq. Revenue Change	-	-	-	-	-

Receivable Turnover Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	#
Healthcare Sector	#
Overall Market	#

Receivable Turnover Ratio Statistics
High	Average	Low
0	0	0

News about Atyr Pharma Inc Receivables Turnover Ratios

Advancements in Anti-Fibrotic Research and Oncology aTyr Pharmas Groundbreaking Studies Highlight Potential Treatmen...

As our understanding of fibrotic diseases and complex tumors such as glioblastoma multiforme (GBM) progresses, novel therapeutic approaches are emerging to offer hope for patients afflicted by these challenging conditions. aTyr Pharma, a biopharmaceutical company dedicated to developing innovative therapies, has recently made significant strides in the field of anti-fibrotic research and oncology, specifically targeting pulmonary fibrosis and GBM. This article synthesizes recent findings from aTyr Pharma s preclinical research on ATYR0101 and the ongoing studies of efzofitimod (formerly known as ATYR094) and anti-NRP2 antibodies at Stanford Medicine. 1. Anti-Fibrotic Effects of ATYR0101: Insights from Keystone Symposia Recently, aTyr Pharma presented preclinical research that underscores the anti-fibrotic properties of ATYR0101 at the Keystone Symposia on Fibrosis. Lung and kidney fibrosis pose a significant challenge in the clinical landscape, marked by excessive extracellular matrix deposition, leading to organ dysfunction and reduced quality of life. Utilizing various models, aTyr Pharma demonstrated that ATYR0101 could mitigate fibrotic progression in both lung and renal tissues. Fibrosis is a pathophysiological response to injury, driven by complex biological mechanisms, including immune cell activation and transforming growth factor-beta (TGF-β) signaling. The data presented indicate that ATYR0101 inhibits these pathways, resulting in reduced collagen deposition and myofibroblast activation, two key features of fibrotic diseases. The research reinforces the potential of ATYR0101 as a therapeutic candidate for patients suffering from these debilitating conditions, contributing to the broader understanding of fibrosis management.

ATYR Company Profile • Back to ATYR Efficiency Comparisons • Compare ATYR Receivables Turnover Ratio to its Competitors

Financial Statements
Atyr Pharma Inc 's Accounts Receivable	$ 0 Millions	Visit ATYR's Balance sheet
Atyr Pharma Inc 's Sales TTM	$ 0 Millions	Visit ATYR's Income Statement
Sources of ATYR's Revenues		Visit ATYR's Sales by Geography

Other Accounts Receivable Turnover Ratios
Biotechnology & Pharmaceuticals Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
ATYR's Receivable Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
ATYR's Growth Rates	ATYR's Roa	ATYR's Inventory Turnover Ratio	ATYR's Dividend Comparisons
ATYR's Profitability Ratios	ATYR's Roi	ATYR's Asset Turnover Ratio	ATYR's Dividend Growth
ATYR's Valuation Ratios	ATYR's Roe	ATYR's Financial Strength Ratios	ATYR's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2026	Receivable at quarter ending Jun 30 2026
Clene Inc	1.15	$ 0.197 Millions	$ 0.171 Millions
Instil Bio Inc	1.15	$ 8.968 Millions	$ 7.822 Millions
Scienture Holdings Inc	1.15	$ 0.821 Millions	$ 0.717 Millions
Regen Biopharma Inc	0.99	$ 0.237 Millions	$ 0.239 Millions
Prokidney Corp	0.75	$ 0.818 Millions	$ 1.088 Millions
Royalty Pharma Plc	0.50	$ 2,535.998 Millions	$ 5,116.482 Millions
Cardiff Lexington Corporation	0.46	$ 10.213 Millions	$ 22.347 Millions

Date modified: 2026-08-14T08:40:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.